1. Home
  2. ANAB vs OFIX Comparison

ANAB vs OFIX Comparison

Compare ANAB & OFIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ANAB

AnaptysBio Inc.

HOLD

Current Price

$47.76

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo Orthofix Medical Inc. (DE)

OFIX

Orthofix Medical Inc. (DE)

HOLD

Current Price

$15.56

Market Cap

622.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANAB
OFIX
Founded
2005
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
622.1M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
ANAB
OFIX
Price
$47.76
$15.56
Analyst Decision
Buy
Strong Buy
Analyst Count
11
5
Target Price
$59.90
$21.50
AVG Volume (30 Days)
490.7K
212.4K
Earning Date
11-04-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$169,467,000.00
$818,058,000.00
Revenue This Year
$135.45
$3.97
Revenue Next Year
N/A
$5.84
P/E Ratio
N/A
N/A
Revenue Growth
196.42
4.31
52 Week Low
$12.21
$10.24
52 Week High
$47.86
$20.48

Technical Indicators

Market Signals
Indicator
ANAB
OFIX
Relative Strength Index (RSI) 73.02 50.66
Support Level $43.92 $15.22
Resistance Level $47.86 $15.93
Average True Range (ATR) 2.34 0.44
MACD 0.06 -0.05
Stochastic Oscillator 91.93 32.37

Price Performance

Historical Comparison
ANAB
OFIX

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About OFIX Orthofix Medical Inc. (DE)

Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.

Share on Social Networks: